Carlsmed Earnings Call Transcripts
Fiscal Year 2026
-
A personalized spine surgery platform is driving rapid adoption, with strong clinical outcomes and operational improvements. Favorable reimbursement changes and new product launches are expected to fuel further growth, while margin expansion and a path to near-term profitability remain key priorities.
-
Q1 2026 revenue grew 58% year-over-year to $16.1M, driven by strong surgeon adoption and new product launches. Gross margin improved to 77.1%, and full-year revenue guidance was raised to $72–77M. CMS reimbursement changes and clinical data support continued growth.
-
Aprevo's digital, AI-driven spine surgery platform has demonstrated strong clinical outcomes, including a 74% reduction in reoperations, and is expanding rapidly in both lumbar and cervical markets. Elevated reimbursement, robust surgeon adoption, and new product launches support a 44% growth outlook for 2024.
-
Rapid revenue growth and strong clinical validation drive adoption of a personalized spine surgery platform, now expanded to both lumbar and cervical procedures. New reimbursement wins and technological innovations support continued U.S. market expansion.
Fiscal Year 2025
-
Achieved 86% revenue growth in 2025, driven by strong lumbar platform performance and new cervical product launches. Gross margins expanded to 75.3%, and 2026 revenue is guided to grow 44% at the midpoint. Cash position remains strong after a successful IPO.
-
A next-generation med tech platform for spine surgery has demonstrated a 74% reduction in reoperation rates and is expanding from lumbar to cervical procedures, targeting a combined 800,000 annual U.S. cases. Enhanced reimbursement, rapid production, and a capital-light model drive strong growth and adoption.
-
Q3 2025 saw 98% revenue growth, 76% gross margins, and a 70% increase in surgeon users, with strong clinical data supporting reduced revision rates. Full-year revenue guidance was raised to $49–$50 million, and the company is well-positioned for the upcoming cervical fusion launch.
-
Q2 2025 revenue nearly doubled year-over-year to $12.1 million, driven by strong surgeon adoption and procedure growth. Full-year revenue is guided to $45.5–$47.5 million, with continued expansion in both lumbar and upcoming cervical fusion markets.